Home / Resources / Videos / ADA 2017 / Ray Kausik Part 1, PCSK9 Inhibitor Treatment For Diabetes

Ray Kausik Part 1, PCSK9 Inhibitor Treatment For Diabetes

In part 1 of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, California about his work targeting PCSK9 with RNA interference to see how that impacts on lipids and clinical outcomes.

Ray Kausik, MB, ChB, MD,  is Professor of Public Health in the Department of Public Health and Primary Care at Imperial College London as well as Honorary Consultant Cardiologist at the Imperial College NHS Trust.

Transcript of this video segment:

Steve Freed: This is Steve Freed with Diabetes In Control and we’re here at the American Diabetes Association 77th Scientific Sessions 2017. We’re here to present you some really exciting interviews with some of the top Endos from all across the world. We have with us a special guest who’s presenting, and that would be Ray Kausik. Maybe we can start out by you telling us a little bit about yourself and what you do.

Ray Kausik: So, I am a professor of public health and consultant cardiologist in London, UK. I’m also a clinical epidemiologist and my background has been in looking at large scale population studies around cardiometabolic risk factors and also leading many trials and participating in many trials. Currently, I’ve been involved with a number of studies of PCSK9 inhibitors, both monoclonal antibodies and also new ways of targeting PCSK9 with RNA interference to see how that impacts on lipids and clinical outcomes.

Freed: So, the title of your presentation is The Inhibition of PCSK9 in Dyslipidemia Patients with Diabetes, & Lipid Management in Individuals with Diabetes and High Cardiovascular Risk, & What Are the Unmet Needs. Can you start off with that and kind of give us a general idea of what your talk is about?

Kausik: Patients with diabetes have a doubling of the risk of future cardiovascular events. Now, some of those are factors we don’t completely understand. It may not be because of having diabetes per se, but some of it is because of additional lipid related abnormalities. In particular, the patient with long-standing type 2 diabetes, particularly with obesity, tend to have a so-called atherogenic dyslipidemia (ADL), which means that they have a low level of LDL, high level of triglyceride and so, even though in these people the LDL levels are particularly high, there is cholesterol carried in these additional triglyceride-rich lipoproteins. It can be potentially modulated by reducing the levels of these proteins to reduce cardiovascular risk. What we also know is that statins will do so much; they will lower LDL cholesterol, but there is still this residual risk that is present. One way to try and target that is to think about having more LDL receptors by using a monoclonal antibody to PCSK9, which increases the survival time in the number of the these LDL receptors because these particles are also cleared by these receptors.